08:00 AM EDT, 08/30/2024 (MT Newswires) -- NuCana ( NCNA ) shares slumped 51% pre-bell Friday after the company ended its phase 2 trial of a prospective treatment for colorectal cancer.

Paltalk ( PALT ) shares retreated 36%, reversing from Thursday's gains.

Elastic (ESTC) shares fell 27% after the company issued fiscal 2025 revenue guidance that trailed analysts' estimates.

Biocardia ( BCDA ) shares dropped 18%, paring Thursday's rally.

Alnylam (ALNY) shares were down 11% after the company reported that its phase 3 trial of an investigational therapy for ATTR amyloidosis with cardiomyopathy showed "non-significant" reduction in mortality in the study's monotherapy group.

Price: 3.78, Change: -3.95, Percent Change: -51.10